Companies like Athira Pharma (), with much smaller market caps, have drug candidates in potentially registrational trials, with apparently safer drugs, and have already reported efficacy of their drug candidates.

Source: https://seekingalpha.com/article/4576265-prothena-im-not-buyer-3-billion-valuation?source=feed_all_articles

Invesco Ltd. bought a new stake in Athira Pharma in the 1st quarter valued at about $138,000.

Source: https://www.etfdailynews.com/2023/06/08/andrew-gengos-buys-45000-shares-of-athira-pharma-inc-nasdaqatha-stock/

Prelude Capital Management LLC bought a new position in Athira Pharma in the first quarter worth approximately $149,000.

Source: https://www.etfdailynews.com/2023/06/08/andrew-gengos-buys-45000-shares-of-athira-pharma-inc-nasdaqatha-stock/